Nexsen (ASX:NXN) has taken a major step toward US market entry with the commencement of engagement with the US Food and Drug Administration for its rapid Group B Streptococcus point-of-care diagnostic.
The company lodged its FDA pre-submission ahead of schedule under the 510(k) pathway, a streamlined regulatory route for medical diagnostics, positioning Nexsen for faster market clearance compared with traditional therapeutic development.
The GBS Rapid Sensor provides lab-grade results in minutes, addressing critical delays in maternal care where timely detection of GBS can directly impact clinical outcomes.
FDA feedback is expected within approximately 70 days, guiding the company's formal 510(k) submission based on ongoing multi-site clinical trials.
In parallel, Nexsen has strengthened its commercial and financial readiness with the appointment of Richard Jarvis as CFO, while its scientific credentials were enhanced as Chief Innovation Officer Professor Vipul Bansal received a distinguished professorship from RMIT University for his global contributions to nanobiotechnology and applied diagnostics.
Managing Director Mark Muzzin said the proactive regulatory engagement and robust clinical data position Nexsen for efficient US market entry and meaningful impact in rapid diagnostics.
At the time of reporting, Nexsen's share price was $0.19.